SCHEMBL1249693

SCHEMBL1249693

CCC(CNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1)N(CC)CC

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 0.70
▸ FGFR2 P21802 14/20 0.70
▸ FGFR4 P22455 14/20 0.70
▸ FGFR3 P22607 14/20 0.70
▸ FLT1 P17948 11/20 0.70
▸ FLT4 P35916 11/20 0.70
▸ KDR P35968 11/20 0.70
▸ SRC P12931 3/20 0.70
▸ GLA P06280 1/20 0.70
▸ CSK P41240 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ ATM Q13315 1/20 0.70
▸ EGFR P00533 1/20 0.62
▸ PDGFRB P09619 2/20 0.52
▸ PDGFRA P16234 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470677 0.86 FGFR1 (0.72) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL22144559 0.83 FGFR1 (0.95) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL19848922 0.83 FGFR1 (0.80) FGFR1FGFR2FGFR4FGFR3FLT1
Pd-173074 SCHEMBL29828472 0.82 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3FLT1
Pd-173074 SCHEMBL177946 0.82 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL31648262 0.82 FGFR1 (0.76) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL3479994 0.82 FGFR1 (0.87) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL30737861 0.81 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL2470675 0.81 FGFR1 (0.85) FGFR1FGFR2FGFR4FGFR3FLT1
SCHEMBL31648009 0.80 FGFR1 (0.78) FGFR1FGFR2FGFR4FGFR3FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105031-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR ESAI R & D MANAGEMENT CO., LTD. (JP) 2010-04-29 — — US claimed
US-20100092490-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-15 — — US claimed
EP-1925676-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 — — EP claimed
EP-1925941-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 — — EP claimed
US-20200199689-A1 Method for Predicting Effectiveness of Angiogenesis Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-06-25 — — US disclosed
US-20170191137-A1 Method For Predicting Effectiveness Of Angiogenesis Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-07-06 — — US disclosed
US-9006240-B2 Method for assay on the effect of vascularization inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-14 — — US disclosed
US-8969344-B2 Method for assay on the effect of vascularization inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-03-03 — — US disclosed
US-20140148483-A1 Method For Predicting Effectiveness Of Angiogenesis Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-05-29 — — US disclosed
EP-2711433-A1 METHOD FOR PREDICTING EFFECTIVENESS OF ANGIOGENESIS INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2014-03-26 — — EP disclosed
US-20130085152-A1 Method For Assay On The Effect Of Vascularization Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-04-04 — — US disclosed
EP-2281901-A2 Anti-tumour pharmaceutical composition with angiogenesis inhibitors Eisai R&D Management Co., Ltd. (JP) 2011-02-09 — — EP disclosed
US-20100105031-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR ESAI R & D MANAGEMENT CO., LTD. (JP) 2010-04-29 — — US disclosed
US-20100092490-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-15 — — US disclosed
EP-1925676-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 — — EP disclosed
EP-1925941-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148483-A1 Method For Predicting Effectiveness Of Angiogenesis Inhibitor VEGFA, BRAF, FLT4 FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885
US-20130085152-A1 Method For Assay On The Effect Of Vascularization Inhibitor VEGFA, EDF1, HDGF FGFR1 81/4885FGFR2 273/4885FGFR4 107/4885
US-20200199689-A1 Method for Predicting Effectiveness of Angiogenesis Inhibitor VEGFA, BRAF, FLT4 FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885
US-20100092490-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR VEGFA, FLT4, MKI67 FGFR1 87/4885FGFR2 220/4885FGFR4 70/4885
US-20170191137-A1 Method For Predicting Effectiveness Of Angiogenesis Inhibitor VEGFA, BRAF, FLT4 FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback